[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 44849
1. |||||||||. 100%  Compston JE: The risks and benefits of HRT. J Musculoskelet Neuronal Interact; 2004 Jun;4(2):187-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risks and benefits of HRT.
  • For many years hormone replacement therapy (HRT) was regarded as the gold standard for treatment of osteoporosis.
  • The current consensus is that HRT is no longer regarded as a front-line option for prevention of osteoporotic fractures and that its use for this purpose should be restricted to women with osteoporosis who have menopausal symptoms and to older women who are intolerant of other therapies and/or express a strong preference for HRT despite being informed about potential adverse effects.
  • Nevertheless, the mechanisms by which estrogen exerts its beneficial skeletal effects remain a major area of research that has important implications for the development of novel therapies.
  • [MeSH-major] Breast Neoplasms / epidemiology. Cardiovascular Diseases / epidemiology. Estrogen Replacement Therapy / adverse effects. Osteoporosis / drug therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • COS Scholar Universe. author profiles.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15615123.001).
  • [ISSN] 1108-7161
  • [Journal-full-title] Journal of musculoskeletal & neuronal interactions
  • [ISO-abbreviation] J Musculoskelet Neuronal Interact
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 25
  •  go-up   go-down


2. ||||||||.. 84%  Balasubramanian M, Bowd C, Weinreb RN, Zangwill LM: Agreement between the Heidelberg Retina Tomograph (HRT) stereometric parameters estimated using HRT-I and HRT-II. Optom Vis Sci; 2011 Jan;88(1):140-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agreement between the Heidelberg Retina Tomograph (HRT) stereometric parameters estimated using HRT-I and HRT-II.
  • PURPOSE: To assess agreement between Heidelberg Retina Tomograph (HRT)-I and HRT-II stereometric parameters and to determine whether parabolic error correction (PEC) to the topographies improves agreement.
  • METHODS: University of California San Diego Diagnostic Innovations in Glaucoma Study participants with two HRT-II examinations (n = 380) or one HRT-I and one HRT-II examinations (n = 344) acquired on the same day were included.
  • From the group of 380 eyes, 200 eyes were randomly selected to estimate the repeatability coefficients of HRT-II rim area and volume, cup area and volume, and mean retinal nerve fiber layer (RNFL) thickness parameters (HRT-II control group), and the remaining 180 eyes were used to assess agreement between two HRT-II examinations (HRT-II study group).
  • Agreement between stereometric parameters of HRT-I and HRT-II examinations (HRT-I vs. HRT-II study group) were assessed with (1) no PEC, (2) HRT PEC, and (3) a modified PEC.
  • RESULTS: In the HRT-II study group, agreement between stereometric parameters was good, with no statistically significant biases.
  • In the HRT-I vs. HRT-II study group, there was a small statistically significant bias between the stereometric parameters, but all differences were within CLA for ≥95% of participants.
  • CONCLUSIONS: Agreement between HRT-I and HRT-II stereometric parameters was good, and PEC did not improve agreement.
  • These results suggest that HRT-I and HRT-II examinations can be used interchangeably to detect changes in stereometric parameters over time.
  • [MeSH-major] Glaucoma / diagnosis. Microscopy, Confocal. Nerve Fibers / pathology. Ophthalmoscopes. Optic Disk / pathology. Retina / pathology. Tomography / methods

  • MedlinePlus Health Information. consumer health - Glaucoma.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1986 Feb 8;1(8476):307-10 [2868172.001]
  • [Cites] Arch Ophthalmol. 2005 Sep;123(9):1188-97 [16157798.001]
  • [Cites] Br J Ophthalmol. 2005 Nov;89(11):1427-32 [16234446.001]
  • [Cites] Br J Ophthalmol. 2005 Nov;89(11):1433-7 [16234447.001]
  • [Cites] Vet Clin Pathol. 2006 Sep;35(3):276-86 [16967409.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5322-30 [17122120.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1156-63 [17325159.001]
  • [Cites] Arch Ophthalmol. 2009 Sep;127(9):1136-45 [19752422.001]
  • [Cites] Eye (Lond). 2011 Jan;25(1):31-42 [20885428.001]
  • [Cites] Clin Chem. 1981 Jul;27(7):1311-2 [7237812.001]
  • [Cites] Stat Methods Med Res. 1999 Jun;8(2):135-60 [10501650.001]
  • [Cites] Ophthalmology. 1998 Aug;105(8):1557-63 [9709774.001]
  • [Cites] Clin Chem. 1997 Nov;43(11):2039-46 [9365386.001]
  • [Cites] Am J Ophthalmol. 1996 Oct;122(4):520-5 [8862049.001]
  • [Cites] BMJ. 1996 Jun 29;312(7047):1654 [8664723.001]
  • [Cites] Am J Ophthalmol. 1995 Apr;119(4):415-21 [7709966.001]
  • [Cites] Ann Clin Biochem. 1992 Sep;29 ( Pt 5):556-60 [1444169.001]
  • [Cites] Clin Chem. 2004 Nov;50(11):2216-8 [15502104.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2003 Jul;241(7):541-5 [12819980.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1126-31 [12601039.001]
  • [Cites] Br J Ophthalmol. 1999 Jun;83(6):664-9 [10340972.001]
  • (PMID = 21037499.001).
  • [ISSN] 1538-9235
  • [Journal-full-title] Optometry and vision science : official publication of the American Academy of Optometry
  • [ISO-abbreviation] Optom Vis Sci
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY11008; United States / NEI NIH HHS / EY / K99 EY020518; United States / NEI NIH HHS / EY / R01 EY011008; United States / NEI NIH HHS / EY / R01 EY011008-14; United States / NEI NIH HHS / EY / R01 EY011008-15
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS252970; NLM/ PMC3014384
  •  go-up   go-down


3. ||||||||.. 79%  Stevenson JC, International Consensus Group on HRT and Regulatory Issues: HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes? Hum Reprod; 2006 Jul;21(7):1668-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?
  • HRT has been widely used for the relief of menopausal symptoms and the prevention and treatment of post-menopausal osteoporosis.
  • However, following the publication of the Women's Health Initiative (WHI) and the Million Women Study (MWS), regulatory authorities issued an urgent safety restriction on HRT use in preventing post-menopausal osteoporosis, recommending that it now be considered a second-line treatment.
  • Of the available therapies, none other than HRT has been clearly demonstrated to prevent hip fractures in such women.
  • Thus, HRT should be recommended as first-line treatment for osteoporosis prevention.
  • Potential risks of HRT, such as increased development of breast cancer and increased thromboembolism, have long been known.
  • When given for the correct indications, HRT is of major benefit to many women.
  • [MeSH-major] Estrogen Replacement Therapy / adverse effects. Osteoporosis, Postmenopausal / prevention & control. Women's Health

  • Genetic Alliance. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Women's Health.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556675.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. |||||||... 67%  Szeto DP, Griffin KJ, Kimelman D: HrT is required for cardiovascular development in zebrafish. Development; 2002 Nov;129(21):5093-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HrT is required for cardiovascular development in zebrafish.
  • The recently identified zebrafish T-box gene hrT is expressed in the developing heart and in the endothelial cells forming the dorsal aorta.
  • Orthologs of hrT are expressed in cardiovascular cells from Drosophila to mouse, suggesting that the function of hrT is evolutionarily conserved.
  • The role of hrT in cardiovascular development, however, has not thus far been determined in any animal model.
  • Using morpholino antisense oligonucleotides, we show that zebrafish embryos lacking hrT function have dysmorphic hearts and an absence of blood circulation.
  • Although the early events in heart formation were normal in hrT morphant embryos, subsequently the hearts failed to undergo looping, and late onset defects in chamber morphology and gene expression were observed.
  • In particular, we found that the loss of hrT function led to a dramatic upregulation of tbx5, a gene required for normal heart morphogenesis.
  • Conversely, we show that overexpression of hrT causes a significant downregulation of tbx5, indicating that one key role of hrT is to regulate the levels of tbx5.
  • Secondly, we found that HrT is required to inhibit the expression of the blood lineage markers gata1 and gata2 in the most posterior lateral plate mesoderm.
  • Finally, we show that HrT is required for vasculogenesis in the trunk, leading to similar vascular defects to those observed in midline mutants such as floating head. hrT expression in the vascular progenitors depends upon midline mesoderm, indicating that this expression is one important component of the response to a midline-derived signal during vascular morphogenesis.
  • [MeSH-minor] Animals. Gene Expression Regulation, Developmental. Heart Defects, Congenital / embryology. Heart Defects, Congenital / genetics. Hematopoiesis / genetics. Hematopoiesis / physiology. Homeodomain Proteins / genetics. Homeodomain Proteins / physiology. Humans. In Situ Hybridization. Mice. Mutation. Oligodeoxyribonucleotides, Antisense / genetics. Oligodeoxyribonucleotides, Antisense / pharmacology. Recombinant Fusion Proteins / genetics. Transcription Factors / genetics. Transcription Factors / physiology

  • Genetics Home Reference. consumer health - GATA1 Gene.
  • Genetics Home Reference. consumer health - TBX5 Gene.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12397116.001).
  • [ISSN] 0950-1991
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / F32 HD08725; United States / PHS HHS / / T32 07312
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Oligodeoxyribonucleotides, Antisense; 0 / Recombinant Fusion Proteins; 0 / T-Box Domain Proteins; 0 / T-box transcription factor 5; 0 / TBX20 protein, human; 0 / Tbx20 protein, mouse; 0 / Transcription Factors; 0 / Zebrafish Proteins; 0 / flh protein, zebrafish; 0 / tbx20 protein, zebrafish
  •  go-up   go-down


5. ||||||.... 64%  Bain CA, Walters MR, Lees KR, Lumsden MA: The effect of HRT on cerebral haemodynamics and cerebral vasomotor reactivity in post-menopausal women. Hum Reprod; 2004 Oct;19(10):2411-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of HRT on cerebral haemodynamics and cerebral vasomotor reactivity in post-menopausal women.
  • We performed a randomized, double-blind placebo-controlled trial to investigate the effect of two HRT preparations upon CVR.
  • METHODS: We examined middle cerebral artery mean flow velocity (MFV), internal carotid artery pulsatility index (PI) and CVR to an i.v. acetazolamide bolus using ultrasound in three groups of post-menopausal women randomized to oral estradiol 1 mg+norethisterone 0.5 mg (group N), estradiol 1 mg+dydrogesterone 5 mg (group D) or placebo (group P).
  • RESULTS: Thirty-eight post-menopausal women were recruited (N=12, D=14, P=12); mean (SE) age was 56.7 (4) years.
  • Neither HRT preparation affected CVR [% (SE) change from baseline N +4.2 (11); D +3.8 (5.5); P +4.0 (3.8); all comparisons P = NS].
  • CONCLUSION: HRT did not alter CVR.
  • The reduced PI and increased MFV suggest HRT-induced intracranial vasodilatation, which is more apparent in dydrogesterone recipients.
  • [MeSH-major] Cerebrovascular Circulation / drug effects. Dydrogesterone / adverse effects. Estradiol / adverse effects. Estrogen Replacement Therapy / adverse effects. Norethindrone / adverse effects. Vasomotor System / drug effects


6. ||||||.... 62%  Poli A, Strouthidis NG, Ho TA, Garway-Heath DF: Analysis of HRT images: comparison of reference planes. Invest Ophthalmol Vis Sci; 2008 Sep;49(9):3970-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of HRT images: comparison of reference planes.
  • PURPOSE: The values of Heidelberg Retinal Tomograph (HRT; Heidelberg Engineering, Heidelberg, Germany) stereometric parameters depend on the reference plane (RP), the instability of which results in parameter variability.
  • METHODS: A longitudinal image series of 31 subjects with ocular hypertension who had reproducible visual field loss and 19 normal subjects was analyzed using five different RPs: the standard RP (HRT software version 3.1.2.0), two 320-mum RPs (software ver.
  • Linear regression of RA over time was performed, and the slope and residual SD (RSD) were calculated for each RP.
  • Comparisons between RPs were made by paired t-tests.
  • There was a trend toward faster RA change/time (mean, -0.0123 mm(2)/y) for the standard RP and slower (-0.0095 mm(2)/y) for the experimental RP.
  • CONCLUSIONS: Compared to the standard RP, the Moorfields RP has significantly lower variability and probably provides a greater facility for discriminating RA change from measurement variability in a longitudinal HRT image series.
  • [MeSH-major] Tomography, Optical / methods. Vision Disorders / physiopathology. Visual Fields / physiology

  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469180.001).
  • [ISSN] 1552-5783
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. ||||||.... 60%  Lee DJ: Cerazette and HRT. J Fam Plann Reprod Health Care; 2007 Jul;33(3):222
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerazette and HRT.
  • [MeSH-major] Contraceptives, Oral, Synthetic / administration & dosage. Desogestrel / administration & dosage. Hormone Replacement Therapy / methods

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • HSDB. structure - DESOGESTREL.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609100.001).
  • [ISSN] 1471-1893
  • [Journal-full-title] The journal of family planning and reproductive health care / Faculty of Family Planning & Reproductive Health Care, Royal College of Obstetricians & Gynaecologists
  • [ISO-abbreviation] J Fam Plann Reprod Health Care
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Synthetic; 81K9V7M3A3 / Desogestrel
  •  go-up   go-down


8. |......... 4%  Cooper IF, Siadaty MS: 'Organophosphorus Compounds' associated with 'Hormone Replacement': Top Publications. BioMedLib Review; OrganophosphorusCompound;HormoneReplacement:707308766. ISSN: 2331-5717. 2014/1/8
PDF icon [Fulltext service] Download fulltext PDF of this article.

  • [Title] 'Organophosphorus Compounds' associated with 'Hormone Replacement': Top Publications.
  • [Transliterated title]
  • Background: There are articles published each month which present 'Organophosphorus Compound' for 'hormone replacement'.
  • Finding such articles is important for researchers, clinicians, and patients.
  • However these articles are spread across thousands of journals, and there are many types of 'Organophosphorus Compound'.
  • This makes searching and locating the relevant publications a challenge.
  • We have used BioMedLib's semantic search technology to address the issue, and gathered all the pertinent publications in this review article.
  • Methods: We categorized the publications we found into two groups.
  • We used the strength of textual-association to separate the groups.
  • In group one there are publications with the strongest evidence of association. We focused finding the most relevant publications pertinent to our goal, rather than combining them into a conclusion section. Such textual synthesis will be the focus of our next project.
  • Results: Group one includes 28 publications, and group two 1727 publications.
  • Here are the top 10.
  • Tiraş MB et al: Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study.
  • Curtiss FR: ERT, HRT, raloxifine, calcitonin, or bisphosphonates for osteoporosis.
  • Ott SM: Making decisions about hormone replacement therapy: bisphosphonates should not be recommended for women aged 50.
  • Yalçin F et al: The effect of menopause, hormone replacement therapy (HRT), alendronate (ALN), and calcium supplements on saliva.
  • Greenspan SL et al: Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.
  • Morishige K et al: Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT.
  • Campbell IA et al: Hormone replacement therapy (HRT) or etidronate for osteoporosis in postmenopausal asthmatics on glucocorticoids: a randomised factorial trial.
  • Nozaki M et al: Combination of intermittent cyclical etidronate and hormone replacement therapy for postmenopausal non-responders to estrogen.
  • Posaci C et al: The values of urinary NTx in postmenopausal women undergoing HRT; the role of additional alendronate therapy.
  • Mobley LR et al: Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2014 Siadaty and Cooper; licensee BioMedLib LLC.
  • (UID = 707308766.001).
  • [ISSN] 2331-5717
  • [Journal-full-title] BioMedLib Review
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] UNITED STATES
  •  go-up   go-down


9. |......... 4%  Cooper IF, Siadaty MS: 'Environmental Effects of Humans' associated with 'Hormone Replacement': Top Publications. BioMedLib Review; EnvironmentalEffectOf;HormoneReplacement:706263400. ISSN: 2331-5717. 2014/4/24
PDF icon [Fulltext service] Download fulltext PDF of this article.

  • [Title] 'Environmental Effects of Humans' associated with 'Hormone Replacement': Top Publications.
  • [Transliterated title]
  • Background: There are articles published each month which present 'Environmental Effect of Humans' for 'hormone replacement'.
  • Finding such articles is important for researchers, clinicians, and patients.
  • However these articles are spread across thousands of journals, and there are many types of 'Environmental Effect of Humans'.
  • This makes searching and locating the relevant publications a challenge.
  • We have used BioMedLib's semantic search technology to address the issue, and gathered all the pertinent publications in this review article.
  • Methods: We categorized the publications we found into two groups.
  • We used the strength of textual-association to separate the groups.
  • In group one there are publications with the strongest evidence of association. We focused finding the most relevant publications pertinent to our goal, rather than combining them into a conclusion section. Such textual synthesis will be the focus of our next project.
  • Results: Group one includes 19 publications, and group two 1504 publications.
  • Here are the top 10.
  • Dunbar SL et al: Effects of hormone replacement therapy on hemodynamic responses of postmenopausal women to passive heating.
  • Feng HJ et al: Effects of temperature and hydraulic residence time (HRT) on treatment of dilute wastewater in a carrier anaerobic baffled reactor.
  • De Clippeleir H et al: OLAND is feasible to treat sewage-like nitrogen concentrations at low hydraulic residence times.
  • Samorì G et al: Nutrient removal efficiency and physiological responses of Desmodesmus communis at different HRTs and nutrient stress condition using different sources of urban wastewater effluents.
  • Du JD et al: [Impact of hydraulic retention time (HRT) in ABR on its operation performance and granular sludge characteristics when treating low-strength wastewater].
  • Eker S et al: Hydraulic residence time effects on performance of an activated sludge unit treating wastewater containing dichlorophenol.
  • Kim YM et al: Effect of HRT on the biological pre-denitrification process for the simultaneous removal of toxic pollutants from cokes wastewater.
  • Huang Z et al: Submerged anaerobic membrane bioreactor for low-strength wastewater treatment: effect of HRT and SRT on treatment performance and membrane fouling.
  • Ligero P et al: Influence of HRT (hydraulic retention time) and SRT (solid retention time) on the hydrolytic pre-treatment of urban wastewater.
  • Maharaj I et al: The role of HRT and low temperature on the acid-phase anaerobic digestion of municipal and industrial wastewaters.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2014 Siadaty and Cooper; licensee BioMedLib LLC.
  • (UID = 706263400.001).
  • [ISSN] 2331-5717
  • [Journal-full-title] BioMedLib Review
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] UNITED STATES
  •  go-up   go-down


10. |||||||||. 152%  Teede HJ: Controversies in HRT. Aust Fam Physician; 2002 May;31(5):413-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies in HRT.
  • BACKGROUND: Short term hormone replacement therapy (HRT) use is well established for menopausal symptom relief.
  • However, the rates and duration of HRT use are increasing in Australia while the benefits and risks of long term HRT remain controversial.
  • OBJECTIVE: To review the evidence for the use of HRT for the prevention of cardiovascular disease (CVD) and osteoporosis as well as the increased risks of thrombosis and, potentially, breast cancer.
  • Extensive epidemiological data suggests that HRT may protect against CVD and fracture, potentially offering significant long term health benefits to postmenopausal women.
  • However, limited controlled trials focusing on CVD prevention have suggested no benefit from HRT.
  • Also, there is limited controlled fracture end point data to support HRT use for the treatment of osteoporosis.
  • Furthermore, potential benefits of long term HRT use need to be balanced against the risks of use, including increased thrombosis and potentially as suggested from epidemiological studies, increased breast cancer.
  • [MeSH-major] Estrogen Replacement Therapy. Risk Assessment. Treatment Outcome

  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12043543.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Estrogens
  • [Number-of-references] 34
  •  go-up   go-down






Advertisement